Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track SEPN with free AI briefings, catalyst countdowns, and dilution alerts.

SEPN · Septerna, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$565.2M Cash on Hand
94.3mo Cash Runway
Follow SEPN by email Get an email when SEPN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SEPN, unsubscribe in one click. Privacy

📣 What SEPN Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
SEP-479 Healthy Volunteers Phase 1 · NCT07433179 Recruiting
SEP-631 Healthy Volunteers Phase 1 · NCT07069036 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

SEPN holds $565.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $18M/quarter from operations, an estimated runway of 94.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 10 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SEPN files for a raise →

👥 Who Owns SEPN

Insiders 25.8% Institutions (239 holders) 74.2% Public and other holders 0%
HolderTypeShares% of sharesAs of
Third Rock Ventures V, L.P.
10% owner
Insider 10,280,050 21.62% 2026-08-12
DRIEHAUS CAPITAL MANAGEMENT LLC Institution (13G, 5%+) 4,433,058 9.32% 2026-06-30
Jeffrey Finer
Chief Executive Officer, Director · +778,712 options
Insider 833,909 1.75% 2026-11-12
RA CAPITAL MANAGEMENT, L.P.
Director, 10% owner · +15,000 options
Insider 725,443 1.53% 2026-08-12
Elizabeth Bhatt
President and COO · +295,562 options
Insider 174,209 0.37% 2026-10-15
Uwe Klein
SVP, Biological Sciences · +132,481 options
Insider 127,533 0.27% 2025-08-18
Daniel D. Long
SVP, Drug Discovery · +119,841 options
Insider 96,412 0.20% 2026-09-01
Alan Ezekowitz
Director · +15,000 options
Insider 35,600 0.07% 2026-11-11
Samira Shaikhly
Chief People Officer · +143,210 options
Insider 793 0.00% 2026-06-29

Share count 47,549,223 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full SEPN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SEPN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.